摘要
目的:探讨原发性食管小细胞癌的诊疗及预后。方法:回顾性总结分析天津医科大学肿瘤医院1981年1月至2006年11月收治的经病理学证实的原发性食管小细胞癌67例,结合文献,讨论该病的治疗及预后。结果:本组病例依据不同情况分别予以手术、化疗、放疗及综合治疗。I+Ⅱa期、Ⅱb期、Ⅲ+IV期中位生存时间分别为13个月、9.5个月、7个月,病理分期越晚生存期越短,差异具有显著性(P<0.05);各治疗方案中,局限期手术+化疗治疗方案中位生存时间为16个月,单纯手术治疗方案中位生存时间为11个月,手术+化疗方案预后优于单纯手术治疗预后(P<0.05);广泛期放疗+化疗方案中位生存时间最长,但各治疗方案间预后无明显差异(P>0.05)。结论:原发性食管小细胞癌恶性程度高,预后差,易早期发生淋巴及远处器官的转移,病人多在12个月内死亡,该病应早期诊断,并选择合理的治疗方案早期治疗,以改善病人预后及提高生活质量。
Objective： To investigate the dignosis,treatment and prognosis of primary esophageal small cell carcinoma （PESCC）. Methods： Retrospective analysis was made on the 67 cases of pathologically testified PESCC that were collected during the period of January 1981 to November 2006.The treatment and prognosis were discussed combined with other literatures. Results： Operation,chemotherapy,radlotherapy, and combined therapy were carried out respectively on the cases according to their different conditions. After treatment, the Ⅰ±Ⅱa stage, Ⅲ stage and Ⅳ stage＇s median survival period were 13 months,9.5 months and 7 months respectively .With the development of the stage,the prognosis become worse and worse,and the difference was significant （P〈0.05）. For limited stage ,among various kinds of treatment methods, operation combined chemotherapy＇s median survival period was 16 months ,and the pure operation＇s median survival period was 11 months.The operation combined chemotherapy treatment scheme was superior to pure operation for the limited stage,and the difference was significant （P〈0.05）.For the extensive stage,the radiotherapy combined chemotherapy treatment scheme＇ s median survival period was longest ,but various kinds of methods had no significant difference （P〉0.05）. Conclusion： PESCC is a highly malignant disease with early extension, most of the patients die within twelve months.So this kind of patients should have dignosis early and have a suitable treatment scheme to improve the prognosis and the life quality of patients.
出处
《天津医科大学学报》
2007年第3期387-389,共3页
Journal of Tianjin Medical University
关键词
食管小细胞癌
诊断
治疗
预后
Small cell carcinoma of the esophagus
Dignosis
Treatment
Prognosis
